AliveCor teams with PulseAI to read smartwatch ECGs in its Kardia app
AliveCor and PulseAI said KardiaCare subscribers will get PulseAI's FDA-cleared rhythm reads on Apple Watch, Galaxy Watch, Fitbit Sense and Withings ScanWatch ECGs in the first half of 2027.
Pulse, covering wearables and health sensors
, 3 min read
H1 2027When the reads reach compatible smartwatches
What to know
- AliveCor's KardiaCare subscribers will get PulseAI's rhythm determinations on ECGs from Apple Watch, Galaxy Watch, Fitbit Sense and Withings ScanWatch.
- On Apple Watch the reads add beat-by-beat detection of premature ventricular contractions (PVCs).
- The companies say the feature arrives in the first half of 2027; no price was given.
AliveCor, the Mountain View, Calif., maker of the Kardia personal ECG devices, has partnered with Belfast software company PulseAI to analyze heart-rhythm recordings taken on other companies' smartwatches. The two companies announced the deal on November 16, 2026.
Under the arrangement, people who pay for AliveCor's KardiaCare subscription will be able to get PulseAI's AI rhythm determinations on electrocardiogram (ECG) recordings from compatible wearables through the Kardia app. The companies said this will be available in the first half of 2027. They did not give a price or say whether KardiaCare's price will change.
It is PulseAI's first partnership for its ECG technology, according to the release. PulseAI chief executive Alan Kennedy and AliveCor chief executive Priya Abani are both quoted in it.
What the reads cover
The partnership rests on PulseAPI SmartWatch, PulseAI software that the US Food and Drug Administration cleared on October 27 under 510(k) number K254226, as we reported. It processes the single-lead (Lead I) ECG a watch records when the wearer touches it with a finger of the other hand. If you are new to how that works, see how a smartwatch ECG works.
The release splits the devices into two groups:
- Apple Watch: rhythm analysis for normal sinus rhythm, atrial fibrillation (AFib), slow heart rate (bradycardia) and fast heart rate (tachycardia), plus beat-by-beat detection that flags sinus rhythm with premature ventricular contractions (PVCs). The release calls PVC detection on Apple Watch the most notable addition.
- Samsung Galaxy Watch, Fitbit Sense and Withings ScanWatch: sinus rhythm, AFib, a flag for noisy recordings, and an average beat calculation.
That split matches the FDA clearance, which gave full rhythm analysis only for Apple Watch Series 6 recordings and standard ECGs, and narrower AFib and sinus rhythm reads for the other brands.
The inconclusive-reading problem
Smartwatch ECG apps often return "inconclusive" when they cannot classify a recording, for example when the heart rate is high or the signal is noisy. The companies say those results create work: manual reviews, repeat recordings and follow-up visits.
They point to a prospective study of 296 participants published in the journal Heart Rhythm, which they say found PulseAI's algorithm detected AFib with higher sensitivity than Apple Watch's built-in algorithm and cut inconclusive interpretations by 92%. Kivorent News has not reviewed the paper; the figures are the companies'.
The release says the aim is to turn wearable recordings into clinical consultations and specialist overreads. Abani said in the release that "consumer wearables have successfully fostered personal wellness," and framed the deal as bringing medical-grade insight to those devices.
What is still unknown
The release does not say which Apple Watch models will be supported, whether the reads will require a doctor's order (the FDA cleared PulseAPI SmartWatch as a prescription device), or how many countries will get the feature. It also gives no figures for KardiaCare subscribers.
Why it matters
Most smartwatch ECG apps answer little more than "AFib or not." This deal would let owners of four major brands get a second, FDA-cleared read and a route to a clinician without buying another device, and it is the first commercial outlet for PulseAI's clearance. It follows other recent work on what watches can detect, including Google's hypertension study. For what "cleared" means here, see our explainer on FDA clearance and approval.
This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.
Sources
- AliveCor and PulseAI Partner to Bring Advanced Cardiac AI Determinations and Clinical Care Platform to Major Consumer Wearables, AliveCor and PulseAI via GlobeNewswire, November 16, 2026
- 510(k) K254226: PulseAPI SmartWatch (letter and summary), U.S. Food and Drug Administration, October 27, 2026
Heart health techWearablesDigital health and AI in careFDA and health regulationApple
Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.